Analyzing Microbot Medical (NASDAQ:MBOT) and Vaso (OTCMKTS:VASO)

Vaso (OTCMKTS:VASO) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Vaso and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaso	2.91%	9.49%	3.16%
Microbot Medical	N/A	-37.06%	-34.44%

Insider & Institutional Ownership

16.3% of Microbot Medical shares are owned by institutional investors. 43.9% of Vaso shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Vaso and Microbot Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaso	0	0	0	0	0.00
Microbot Medical	1	1	2	0	2.25

Microbot Medical has a consensus target price of $8.75, suggesting a potential upside of 375.54%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than Vaso.

Volatility and Risk

Vaso has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vaso and Microbot Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaso	$86.77 million	0.37	$950,000.00	$0.01	18.06
Microbot Medical	N/A	N/A	-$11.44 million	($0.45)	-4.09

Vaso has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Vaso, indicating that it is currently the more affordable of the two stocks.

Summary

Vaso beats Microbot Medical on 8 of the 13 factors compared between the two stocks.

About Vaso

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.